There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying effects in Parkinson's disease (PD) for over 20 years in various clinical trials. This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD. Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug. Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles, some of which may be insurmountable. © 2013 Teo and Ho; licensee BioMed Central Ltd.
CITATION STYLE
Teo, K. C., & Ho, S. L. (2013, September 8). Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson’s disease. Translational Neurodegeneration. BioMed Central Ltd. https://doi.org/10.1186/2047-9158-2-19
Mendeley helps you to discover research relevant for your work.